Why is Medicamen Biotec falling/rising?

As of 23-Oct, Medicamen Biotech Ltd is experiencing a significant rise in its stock price, currently at Rs 367.30, which reflects an increase of Rs 42.5 or 13.08%. The stock has shown strong performance today, outperforming its sector by 13.29% and achieving a consecutive gain over the last four days, resulting in a total return of 16.68% during this period. Despite this positive momentum, the stock has faced challenges in the longer term, with year-to-date returns down by 27.87% and a substantial decline of 59.59% over the past three years. Additionally, there has been a notable decrease in investor participation, with delivery volume dropping by 80.87% against the five-day average, indicating a potential concern for sustained interest in the stock.
In the broader market context, Medicamen Biotech's recent performance stands in stark contrast to the benchmark Sensex, which has only increased by 1.30% over the past week and 2.99% over the past month. While the stock has shown impressive short-term gains, its year-to-date performance remains significantly lower than the Sensex's 8.21% increase. This divergence highlights the stock's volatility and the potential for rapid price movements, as evidenced by its intraday volatility of 5.85%. Overall, while the stock is currently rising, its long-term performance and declining investor participation may pose risks for future stability.